



(51) International Patent Classification:

A61K 31/352 (2006.01) A61K 9/00 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/036758

(22) International Filing Date:

12 July 2022 (12.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/220,938 12 July 2021 (12.07.2021) US

(71) Applicant: INTEGRATIVE THERAPY DISCOVERY

LAB S.R.L. [IT/US]; c/o The Roy Gross Law Firm, LLC,
50 Washington Street, Suite 910/911, Norwalk, Connecticut
06854 (US).

(72) Inventors: NABISSI, Massimo; C.da Santa Maria in Alto-

cielo 32, 62026 San Ginesio (IT). MARINELLI, Oliviero;
C.da San Giovanni di Colonnella 164, 64010 Colonnella-

la (IT). AGUZZI, Cristina; Via Campania 19, 60015
Falconara Marittima (IT). ZEPPA, Laura; Via Andrea
D'Accorso 6/A, 62032 Camerino (IT). MORELLI, Maria
Beatrice; via San Tommaso n° 130, 63812 Montegranaro
(IT).

(74) Agent: GROSS, Roy D.; 50 Washington Street, Suite
910/911, Norwalk, Connecticut 06854 (US).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: USE OF PHYTOCANNABINOID FOR TREATING ENDOMETRIAL CANCER AND ENDOMETRIOSIS

ISHIKAWA

Fig.1



(57) Abstract: The present disclosure relates to methods and compositions of suitable phytocannabinoids such as cannabidivarin, cannabinol, cannabigerol, cannabidiol, delta9-tetrahydrocannabinol, cannabichromene, or combinations with or without cannabidiol thereof, with the proviso that the at least one phytocannabinoid does not comprise cannabidiol in single administration for treatment endometrial cancer and endometriosis and/or similar conditions, diseases, or disorders.

